Loading ...

David Ikle, PhD

Rho

Sr. Statistical Scientist

Assessment Group

Transplantation

David_Ikle@rhoworld.com

Work:

919-595-6378

Mobile:

919-408-0999

Address:

Rho

Committees:

,

Studies:

ITN010ST

-

Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant

ITN013ST

-

Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults

ITN020AI

-

Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis

ITN021AI

-

Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis

ITN022ST

-

Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients

ITN023ST

-

Belatacept to Prevent Organ Rejection in Kidney Transplant Patients

ITN024ST

-

Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients

ITN030ST

-

Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant

ITN036ST

-

Renal Allograft Tolerance through Mixed Chimerism

ITN039ST

-

Research Study of ATG and Rituximab in Renal Transplantation

ITN524ST-CTOT-12

-

Associating Renal Transplantation With the ITN Signature of Tolerance

ITN816AS

-

A Screening Study for Identification of Tolerance Markers in Liver Transplant Recipients Who Received Campath-1H Immunosuppression

Bio:

Admin Links

Shortcuts

ITN Documents

Links